Theragnostic biomarkers like IDO1, s-CTLA-4, IFN-γ, TNF-α and IL-2 have been studied in various tumors, and seems to hold significant potential in mapping the tumor microenvironment and predicting response to ICPIs. This evidence concerns the gene IFNG and neoplasm.